T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors

Thrombosis and Haemostasis

Volumn 76, Issue 1, 1996, Pages 17-22

  Singer, Sylvia T ^a   Addiego Jr , Joseph E ^a   Reason, Donald C ^b   Lucas, Alexander H ^b  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; HEMOPHILIA A; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030035721     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650515     Document Type: Article

References (46)

1. Hoyer LW, Hemophilia A. N Engl J Med 1994; 330: 38-47.
2. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
3. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-4.
4. Lusher J, Arkin S, Abildgaard CF, Hurst D, the Kogenate PUP Study Group and other participating institutions. Kogenate treatment of previously untreated patients (PUPS) with hemophilia A: Update of safety, efficacy, and inhibitor development after five study years. Blood 1994 (abstr); 84: 239a.
5. Kasper CK. Treatment of factor VIII inhibitors. Prog Hemost Thromb 1989; 9: 57-86.
6. Lubahn BC, Reisner HM. Characterization of a monoclonal anti-idiotype antibody to human anti-factor VIII antibodies. Proc Natl Acad Sci USA 1990; 87: 8232-6.
7. Scandella D, Mattingly M, de Graaf S, Fulcher CA. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618-26.
8. Arai MD, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies: Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83: 1978-84.
9. 365 of the factor VIII heavy chain. J Clin Invest 1988; 82: 123-8.
10. Lollar P, Parker ET, Curtis JE, Helgerson SL, Hoyer LW, Scott ME, Scandella D. Inhibition of human factor Villa by anti-A2 subunit antibodies. J Clin Invest 1994; 93: 2497-504.
11. Fulcher CA, Mahonney de SG, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-80.
12. Scandella D, Nakai H, Felch M, Prescott R, Bray G, Hurst D and the Recombinate and Kogenate Study Groups. Determination of anti-factor VIII antibodies responsible for the inhibitor titer in hemophiliacs treated with plasma or recombinant factor VIII and in spontaneous inhibitors. Blood 1994 (abstr); 84: 240a.
13. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 11601-5.
14. Rizza CR, Matthews JM. Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs. Br J Hematol 1982; 52: 13-24.
15. Shapiro SS. Genetic predisposition to inhibitor formation. In: Factor VIII Inhibitors. Hoyer LW (ed). New York, NY, Alan R. Liss, Inc. 1984, pp 45-56.
16. Aly AM, Aledort LM, Lee TD, Hoyer LW. Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. Br J Haematol 1990; 76: 238-41.
17. Tuddenham EGD, Schwaab R, Seehafer J, Millar DS, Gitschier J, Higuchi M, Bidichandani S, Connor JM, Hoyer LW, Yoshioka A, Peake IR, Olek K, Kazazian HH, Lavergne JM, Giannelli, Antonarakis SE, Cooper DN. Hemophilia A. database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Res 1994; 22: 4851-68.
18. Figueiredo MS, Bernardi F, Zago MA. A novel deletion of FVIII gene associated with variable levels of FVIII inhibitor. Eur J Haematol 1992; 48: 152-4.
19. Lakich D, Kazazian Jr HH, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nature Genetics 1993; 5: 236-41.
20. Goodeve AC, Preston FE, Peake IR. Factor VIII gene rearrangements in patients with severe hemophilia A. Lancet 1994; 343: 329-30.
21. Antonarakis SE, Rossiter JP, Young M, Horst J, de Moerloose P, Sommer SS, Ketterling RP, Kazazian Jr HH, Négrier C, Vinciguerra C, Gitschier J, Goossens M, Girodon E, Ghanem N, Plassa F, Lavergne JM, Vidaud M, Costa JM, Laurian Y, Lin SW, Lin SR, Shen MC, Lillicrap D, Taylor SAM, Windsor S, Valleix SV, Nafa K, Sultan Y, Delpech M, Vnencak-Jones CL, Phillips JA, Ljung RCR, Koumbarelis E, Gialeraki A, Mandalaki T, Jenkins PV, Collins PW, Pasi KJ, Goodeve A, Peake I, Preston FE, Schwartz M, Scheibel E, Ingerslev J, Cooper DN, Millar DS, Kakkar VV, Giannelli F, Naylor JA, Tizzano EF, Baiget M, Domenech M, Altisent C, Tusell J, Beneyto M, Lorenzo JI, Gaucher C, Mazurier C, Peerlinck K, Matthijs G, Cassiman JJ, Vermylen J, Mon PC, Acquila M, Caprino D, Inaba H. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995; 86: 2206-12.
22. Millar DS, Kakkar VV, Cooper DN. Screening for inversions in the factor VIII (F8) gene causing severe hemophilia A. Blood Coag Fibrinol 1994; 5: 239-42.
23. Frommel D, Allain JP. Genetic predisposition to develop factor VIII anti-body in classic hemophilia. Clin Immunol Immunopathol 1977; 8: 34-8.
24. Addiego JE, Kasper C, Abildgaard C, Lusher J, Hilgartner M, Glader B, Aledort L, Hurst D, Bray G. Increased frequency of inhibitors in African American hemophilia A patients. Blood 1994 (abstr); 84: 239a.
25. Allain JP, Verroust F. The response to factor VIII infusion in inhibitor patients. In: Factor VIII Inhibitors. Hoyer LW, ed, New York, NY, Alan R. Liss, Inc. 1984; pp 99-108.
26. Littlewood JD, Bevan SA, Kemball-Cook G, Evans RJ, Barrowcliffe TW. Variable inactivation of human factor VIII from different sources by human factor VIII inhibitors. Br J Haematol 1991; 77: 535-8.
27. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, Smit C, Strengers PFW, Briët E, and the Dutch Hemophilia Study Group. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 1993; 81: 2180-6.
28. Kasper CK, Aledort LM, Counts RB. A more uniform measure of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
29. Bayer AG, Germany. Recombinant factor VIII. Proceedings of the First International Symposium on Recombinant Factor VIII held on August 26, 1989 in Tokyo, Japan. Seminars in Hematology 1991; 28: 1.
30. Weiner MDS, Bianco C, Nussenzweig V. Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes. Blood 1973; 42: 939-46.
31. Madhok R, Smith J, Jenkins A, Lowe DO. T cell sensitization to factor VIII in haemophilia A? Br J Haem 1991; 79: 235-8.
32. Bray GL, Kroner BL, Arkin S, Aledort LW, Hilgartner MW, Eyster ME, Ragni MV, Goedert JJ. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: A report from the multi-center hemophilia cohort study. Am J Hem 1993; 42: 375-9.
33. Ragni MV, Bontempo FA, Lewis JH. Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC. Transfusion 1989: 29: 447-9.
34. Leyva WH, Knusten AP, Joist JH. Disappearance of a high responder factor vm inhibitor in a hemophiliac with AIDS. Am J Clin Pathol 1988; 89: 414-8.
35. Algiman M, Dietrich G, Nydegger UE, Boieldieu D, Sultan Y, Kazatchkine MD. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci USA 1992; 89: 3795-9.
36. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994; 94: 1496-505.
37. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1982; 45: 200-4.
38. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077-81.
39. Burns J, Rosenzweig A, Zweiman B, Lisak RB. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol 1983; 81: 435-40.
40. Pette M, Fujita K, Wilkinson D, Altmann DM, Trowsdale J, Giegerich G, Hinkkanen A, Epplen JT, Kappos L, Wekerle H. Myelin autoreactivity in multiple sclerosis: Recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci USA 1990; 87: 7968-72.
41. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346: 183-7.
42. Filion M, Devine D, Decarv F, Chartrand P. In vitro presentation of platelet antigen GPIIB-IHA initiates T-cell proliferation even with immuno-compatible individual. Blood 1992 (abstr); 80: 49a.
43. Kuwana M, Medsger TA, Wright TM. T cell proliferate response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. J Clin Invest 1995; 96: 586-96.
44. Tordai A, Fenton JW II, Andersen T, Gelfand EW. Functional thrombin receptors on human T lymphoblastoid cells. J Immunol 1993; 150: 4876-86.
45. Tiarks C, Humphreys RE, Anderson J, Mole J, Pechet L. Hypothesis for the control of clotting factor VIII inhibitory antibodies by decreasing potency of helper T-cell-recognized epitopes in factor VIII. Scand J Immunol 1992; 36: 653-60.
46. Hoyer LW. Future approaches to factor VIII inhibitor therapy. Amer J Med 1991; 91: 5A-40S-47S.